Back to top
more

AcelRx Pharmaceuticals, Inc. (ACRX)

(Delayed Data from NSDQ)

$3.66 USD

3.66
1,585,684

+0.10 (2.81%)

Updated May 3, 2019 04:00 PM ET

After-Market: $3.65 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

What Makes AcelRx Pharmaceuticals (ACRX) a New Buy Stock

AcelRx Pharmaceuticals (ACRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Tops Revenue Estimates

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 22.64% and 216.25%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 21.85% and 19.01%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

VAXART, INC. (VXRT) Reports Q2 Loss, Tops Revenue Estimates

VAXART, INC. (VXRT) delivered earnings and revenue surprises of 15.79% and 1,258%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

AcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 100% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of 4.55% and 36.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q1 Earnings Expected to Decline

Crinetics Pharmaceuticals, Inc. (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -900% and 97.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 21.67% and 7.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Misses Revenue Estimates

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0% and 5%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Cronos Group (CRON) Reports Q2 Loss, Lags Revenue Estimates

Cronos (CRON) delivered earnings and revenue surprises of 0% and 16.65%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

AcelRx Pharmaceuticals (ACRX) Reports Q1 Loss, Lags Revenue Estimates

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0% and 11.60%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Acutus Medical, Inc. (AFIB) Reports Q1 Loss, Tops Revenue Estimates

Acutus Medical, Inc. (AFIB) delivered earnings and revenue surprises of -1.01% and 29.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Organogenesis (ORGO) Q1 Earnings Lag Estimates

Organogenesis (ORGO) delivered earnings and revenue surprises of -80% and 2.05%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Misses Revenue Estimates

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0% and 99.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Aziyo Biologics, Inc. (AZYO) Reports Q4 Loss, Lags Revenue Estimates

Aziyo Biologics, Inc. (AZYO) delivered earnings and revenue surprises of -28.13% and 2.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Lags Revenue Estimates

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0.00% and -19.46%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Will AcelRx Pharmaceuticals (ACRX) Report Negative Q2 Earnings? What You Should Know

AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AcelRx (ACRX) Inks Agreement With Aguettant for Dzuveo in Europe

AcelRx (ACRX) enters a licensing agreement for Dzuveo in Europe and an in-licensing agreement for two products in the United States.

AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 16.67% and -1.60%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Will AcelRx Pharmaceuticals (ACRX) Report Negative Q4 Earnings? What You Should Know

AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Do Options Traders Know Something About AcelRx (ACRX) Stock We Don't?

Investors need to pay close attention to AcelRx (ACRX) stock based on the movements in the options market lately.